Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
Elisabeth Buur StougaardEllen BurgessDorte VistisenPhillip BanksManon GirardMichael J DaviesFrederik PerssonPublished in: Diabetes, obesity & metabolism (2023)
This analysis provides additional clinical results that may positively balance the benefit/risk assessment of SGLT inhibition use in T1D.
Keyphrases